The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis

被引：1

作者：

Wang, Zerong ^{[1
]}

Jin, Xuelian ^{[1
]}

Zeng, Jiajia ^{[1
]}

Xiong, Zilin ^{[1
]}

Chen, Xinchuan ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

来源：

ANNALS OF HEMATOLOGY | 2024年 / 103卷 / 09期

关键词：

Myelofibrosis; JAK inhibitors; Ruxolitinib; Allogeneic hematopoietic stem cell transplantation; Poor implantation; Graft-versus-host disease; GANDOTINIB LY2784544; COMFORT-II; RUXOLITINIB; OUTCOMES; SAFETY; DISEASE; PACRITINIB; FEDRATINIB; EFFICACY; THERAPY;

D O I：

10.1007/s00277-024-05703-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with a poor prognosis, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with curative potential. Ruxolitinib, a JAK1/2 inhibitor, has shown promising results in improving patients' symptoms, overall survival, and quality of life, and can be used as a bridging therapy to HSCT that increases the proportion of transplantable patients. However, the effect of this and similar drugs on HSCT outcomes is unknown, and the reports on their efficacy and safety in the peri-transplantation period vary widely in the published literature. This paper reviews clinical data related to the use of JAK inhibitors in the peri-implantation phase of hematopoietic stem cell transplantation for primary myelofibrosis and discusses their efficacy and safety.

引用

页码：3293 / 3301

页数：9

共 68 条

[11] Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients [J].

Davis, Joanne E. ;

Du, Kelei ;

Ludford-Menting, Mandy J. ;

Prabahran, Ashvind ;

Wong, Eric ;

Huntington, Nicholas D. ;

Koldej, Rachel M. ;

Ritchie, David S. .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[12] U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis [J].

Deisseroth, Albert ;

Kaminskas, Edvardas ;

Grillo, Joseph ;

Chen, Wei ;

Saber, Haleh ;

Lu, Hong L. ;

Rothmann, Mark D. ;

Brar, Satjit ;

Wang, Jian ;

Garnett, Christine ;

Bullock, Julie ;

Burke, Laurie B. ;

Rahman, Atiqur ;

Sridhara, Rajeshwari ;

Farrell, Ann ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2012, 18 (12) :3212-3217

[13] Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis [J].

Devos, Timothy ;

Selleslag, Dominik ;

Granacher, Nikki ;

Havelange, Violaine ;

Benghiat, Fleur Samantha .

HEMATOLOGY, 2022, 27 (01) :23-31

[14] Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib [J].

Elli, Elena Maria ;

Borate, Claudia ;

Mendicino, Francesco ;

Palandri, Francesca ;

Palumbo, Giuseppe Alberto .

FRONTIERS IN ONCOLOGY, 2019, 9

[15] Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how? [J].

England, James ;

Gupta, Vikas .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2021, (01) :453-462

[16] JAK-STAT in Early Hematopoiesis and Leukemia [J].

Fasouli, Eirini Sofia ;

Katsantoni, Eleni .

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9

[17] Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS-911543 JAK2 inhibitor [J].

Gangat, Naseema ;

Begna, Kebede H. ;

Al-Kali, Aref ;

Hogan, William ;

Litzow, Mark ;

Pardanani, Animesh ;

Tefferi, Ayalew .

BLOOD CANCER JOURNAL, 2023, 13 (01)

[18] Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study [J].

Gupta, Vikas ;

Kosiorek, Heidi E. ;

Mead, Adam ;

Klisovic, Rebecca B. ;

Galvin, John P. ;

Berenzon, Dmitriy ;

Yacoub, Abdulraheem ;

Viswabandya, Auro ;

Mesa, Ruben A. ;

Goldberg, Judith ;

Price, Leah ;

Salama, Mohamed E. ;

Weinberg, Rona Singer ;

Rampal, Raajit ;

Farnoud, Noushin ;

Dueck, Amylou C. ;

Mascarenhas, John O. ;

Hoffman, Ronald .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (02) :256-264

[19] The regulation of JAKs in cytokine signaling and its breakdown in disease [J].

Hammaren, Henrik M. ;

Virtanen, Anniina T. ;

Raivola, Juuli ;

Silvennoinen, Olli .

CYTOKINE, 2019, 118 :48-63

[20] Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms [J].

Hanif, A. ;

Hari, P. N. ;

Atallah, E. ;

Carlson, K-S B. ;

Pasquini, M. C. ;

Michaelis, L. C. .

BONE MARROW TRANSPLANTATION, 2016, 51 (04) :617-618

← 1 2 3 4 5 6 7 →